Shanghai Fosun Pharmaceutical
Shanghai Fosun Pharmaceutical a leading healthcare company in China.
Launch date
Employees
Market cap
AUD10.9b
Enterprise valuation
AUD14.7b (Public information from Sep 2024)
Share price
HKD12.04 2196.HK
Shanghai Shanghai (HQ)
Notable known LPs: Sinopharm Holding GuoDa Drug Store Company, National Trust
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 30.3b | 39.0b | 44.0b | 41.4b | 42.6b | 47.0b | 50.2b |
| % growth | 6 % | 29 % | 13 % | (6 %) | 3 % | 10 % | 7 % |
| EBITDA | 6.9b | 9.3b | 10.6b | 8.4b | 5.1b | 6.2b | 7.1b |
| % EBITDA margin | 23 % | 24 % | 24 % | 20 % | 12 % | 13 % | 14 % |
| Profit | 3.7b | 4.7b | 3.7b | 2.4b | 2.8b | 3.7b | 4.4b |
| % profit margin | 12 % | 12 % | 8 % | 6 % | 7 % | 8 % | 9 % |
| EV / revenue | 4.6x | 3.3x | 2.3x | 2.0x | 1.6x | 1.5x | 1.3x |
| EV / EBITDA | 20.2x | 13.7x | 9.4x | 9.7x | 13.4x | 11.3x | 9.4x |
| R&D budget | 2.8b | 3.8b | 4.3b | 4.3b | - | - | - |
| R&D % of revenue | 9 % | 10 % | 10 % | 10 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
* | CNY300m | Post IPO Equity | |
| Total Funding | - | ||
Related Content
Recent News about Shanghai Fosun Pharmaceutical
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
ACQUISITION by BioMérieux Apr 2018
exited
ACQUISITION by Shanghai Fosun Pharmaceutical Mar 2017
ACQUISITION by Alphatec Spine Dec 2020
ACQUISITION by Shanghai Fosun Pharmaceutical Oct 2017
ACQUISITION by Shanghai Fosun Pharmaceutical Jun 2024